More than 15 million people in the US, UK, Germany, and France are unaware they have the most aggressive form of fatty liver disease, known as metabolic dysfunction-associated steatotic liver disease (MASLD). This condition primarily affects individuals who consume little to no alcohol and have over 5% fat in their liver. Alarmingly, many of these individuals are at risk for serious health complications.
- 15 million people unaware of fatty liver disease
- MASLD affects non-drinkers with liver fat
- MASH linked to diabetes and obesity
- Diagnosis rates for MASH are alarmingly low
- Economic costs of undiagnosed MASH significant
- Weight loss drugs may improve liver health
Research indicates that about two-thirds of patients with type 2 diabetes may have MASLD, which is also linked to obesity and cardiovascular issues. As of 2025-06-05 19:26:00, it’s estimated that 5% of adults globally suffer from the most severe form of this disease, metabolic dysfunction-associated steatohepatitis (MASH), which can lead to cirrhosis and liver cancer. Yet, nearly 16.7 million individuals remain undiagnosed.
Why are so many people unaware of their condition? The low diagnosis rates highlight a significant gap in healthcare. Many patients with MASH are not being screened, leading to dire health consequences.
- Get screened if you have type 2 diabetes or obesity.
- Consult a healthcare provider about liver health assessments.
- Consider lifestyle changes to improve overall health.
- Discuss weight loss medications if appropriate.
As awareness grows, it’s essential for individuals at risk to seek regular health assessments. Early detection can make a significant difference in treatment outcomes and overall health.
